News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
320,679 Results
Type
Article (18474)
Company Profile (121)
Press Release (302084)
Section
Business (88550)
Career Advice (1293)
Deals (17447)
Drug Delivery (49)
Drug Development (60840)
Employer Resources (60)
FDA (8935)
Job Trends (7446)
News (172939)
Policy (15177)
Tag
Academia (1199)
Africa (403)
Allergies (28)
Alliances (17498)
Alzheimer's disease (732)
Antibody-drug conjugate (ADC) (33)
Approvals (8910)
Arizona (31)
Artificial intelligence (26)
Asia (20902)
Australia (3732)
Bankruptcy (135)
Best Places to Work (6066)
Biosimilars (30)
Breast cancer (28)
C2C Services and Suppliers (27695)
California (753)
Canada (415)
Cancer (178)
Career advice (1016)
Cell therapy (44)
China (42)
Clinical research (48569)
Collaboration (47)
COVID-19 (2093)
Cystic fibrosis (42)
Data (47)
Diabetes (38)
Diagnostics (3101)
Drug pricing (28)
Earnings (50710)
Employer resources (52)
Europe (46219)
Events (50508)
FDA (8998)
Florida (73)
Funding (36)
Gene therapy (34)
Georgia (29)
GLP-1 (444)
Government (2336)
Healthcare (9573)
Hotbed/Location (222099)
Idaho (24)
Illinois (62)
Indiana (67)
Infectious disease (2099)
Inflammatory bowel disease (55)
Interviews (240)
IPO (9960)
Job creations (1442)
Job search strategy (900)
Kansas (39)
Layoffs (176)
Legal (2433)
Liver cancer (39)
Lung cancer (33)
Maine (29)
Manufacturing (31)
Maryland (146)
Massachusetts (601)
Medical device (6177)
Medtech (6177)
Mergers & acquisitions (7410)
Metabolic disorders (164)
Michigan (37)
Minnesota (84)
Neuroscience (789)
New Hampshire (26)
New Jersey (196)
New York (244)
NextGen Class of 2024 (2640)
Non-profit (1823)
North Carolina (242)
Northern California (388)
Obesity (114)
Ohio (45)
Opinion (78)
Peanut (25)
Pennsylvania (242)
People (14937)
Phase I (13646)
Phase II (24003)
Phase III (15657)
Postmarket research (1575)
Preclinical (4559)
Rare diseases (59)
Real estate (1728)
Recruiting (29)
Regulatory (10909)
Research institute (1150)
Resumes & cover letters (254)
South America (562)
Southern California (308)
Startups (1327)
Texas (58)
United States (3202)
Vaccines (306)
Washington State (85)
Weight loss (100)
Date
Today (121)
Last 7 days (499)
Last 30 days (1573)
Last 365 days (23407)
2024 (14092)
2023 (24443)
2022 (29984)
2021 (32062)
2020 (30536)
2019 (22703)
2018 (17293)
2017 (17518)
2016 (15308)
2015 (18682)
2014 (13373)
2013 (9816)
2012 (10616)
2011 (11095)
2010 (9732)
320,679 Results for "2".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Reveal Genomics® HER2DX® Genomic Test Demonstrates Significant Potential in HER2-Positive Advanced Gastric Cancer
Reveal Genomics ® HER2DX ® Genomic Test Demonstrates Significant Potential in HER2-Positive Advanced Gastric Cancer.
June 27, 2024
·
5 min read
Drug Development
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
IMUNON, Inc. announces database lock for its Phase 2 OVATION 2 Study evaluating the safety and efficacy of IMNN-001 in patients with advanced ovarian cancer.
June 24, 2024
·
6 min read
Approvals
Servier Gets FDA Approval for First Targeted Therapy for Grade 2 IDH-Mutant Glioma
Servier Pharmaceuticals’ vorasidenib on Tuesday secured the FDA’s green light for the treatment of patients with grade 2 gliomas carrying mutations in the IDH gene.
August 7, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the completion of a randomized, double-blind, placebo-controlled Phase 2 study of LD IL-2 in patients with mild-to-moderate AD.
May 22, 2024
·
11 min read
Drug Development
Aphaia Pharma Completes Enrollment in Arm 2 of Phase 2 Trial in Individuals with Obesity
Aphaia Pharma announced that it has completed enrollment in the second arm of its Phase 2 trial, which is evaluating the safety and efficacy of two separate doses of Aphaia’s formulation, or their respective placebos, twice per day to induce weight loss in individuals with obesity.
June 13, 2024
·
3 min read
REVEAL GENOMICS® HER2DX® Genomic Test to Be Validated in Pivotal ECOG-ACRIN CompassHER2 pCR Trial in HER2+ Breast Cancer
REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, announced the forthcoming prospective validation of its groundbreaking diagnostic tool HER2DX® within the framework of the ongoing CompassHER2 pCR Trial.
May 14, 2024
·
6 min read
TROP2 (Trophoblast Cell-surface Antigen 2) Targeted Cancer Therapy Market Detailed Analysis and Forecast 2024-2031
Global TROP2 (Trophoblast Cell-surface Antigen 2) Targeted Cancer Therapy Market- (By Application (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Pancreatic Cancer, and Others)),
May 24, 2024
·
1 min read
Business
Qurient Therapeutics Enters CRADA with the National Cancer Institute to Collaborate on a Phase 1/2 Clinical Study of Q901 in Combination with TROP2-ADC
Qurient Therapeutics Enters CRADA with the National Cancer Institute to Collaborate on a Phase 1/2 Clinical Study of Q901 in Combination with TROP2-ADC.
May 21, 2024
·
2 min read
Drug Development
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors
IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced clinical program updates for IDE397, a potential first-in-class Phase 2 MAT2A inhibitor targeting MTAP-deletion solid tumors.
June 24, 2024
·
5 min read
Drug Development
A2 Bio Announces First Patient Dosed in EVEREST-2 Phase 1 Clinical Trial of Novel Mesothelin Logic-Gated CAR T
A2 Biotherapeutics, Inc. today announced dosing of the first patient in the Phase 1 clinical trial of A2B694.
May 16, 2024
·
3 min read
1 of 32,068
Next
